Clinicopathological and functional analysis of carbohydrate antigen expression : Focusing on DU-PAN-2 (precursor of CA19-9)

碳水化合物抗原表达的临床病理学和功能分析：关注DU-PAN-2（CA19-9的前体）

• 批准号: 14570166
• 负责人: YASUDA Masanori
• 金额: $ 1.47万
• 依托单位: Tokai University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14570166/
• 关键词: endometrial adenocarcinoma; carbohydrate antigen; DU-PAN-2; CA19-9; 体癌; 1型糖鎖; 腫瘍マーカー

Serum elevations of carbohydrate antigens ; DU-PAN-2 and CA19-9 in endometrial adenocarcinomas (EACs) were characterized, particularly focusing on clarification of DU-PAN-2 expression profiles. Sixty-four resected EACs of endometrioid type were used. The preoperative serum values of the markers were measured and comparatively analyzed regarding the relationship between histological grade and clinicopathological stage. The overall ratios of positive cases were 26.2% for DU-PAN-2 and 25.0% for CA19-9. DU-PAN-2 decreased as the grading went up, however the reverse was true with CA19-9. During staging-up from I+II to III+IV, the positive ratios inclined as follows : DU-PAN-2, 18.4% to 53.3% ; CA19-9, 20.4% to 40.0%. It is suggested that DU-PAN-2 tends to be produced more in well-differentiated components of EACs than in poorly-differentiated ones. Since approximately half the cases with BAGs were serologically positive for DU-PAN-2 in stage III+IV, the marker is believed to be one of much use for monitoring the cases with an extrauterine extent.

血清碳水化合物抗原升高；我们对子宫内膜腺癌（EACs）中的DU-PAN-2和CA19-9进行了表征，特别关注于澄清DU-PAN-2的表达谱。使用64例切除的子宫内膜样型EACs。测定术前血清各项指标，比较分析组织学分级与临床病理分期的关系。DU-PAN-2阳性率为26.2%，CA19-9阳性率为25.0%。DU-PAN-2随着分级的增加而降低，而CA19-9则相反。从I+II阶段到III+IV阶段，DU-PAN-2阳性率为18.4% ~ 53.3%；CA19-9, 20.4% ~ 40.0%。结果表明，在分化良好的EACs组分中，DU-PAN-2的产生比在分化较差的EACs组分中更多。由于大约一半的bag患者在III+IV期血清学上呈DU-PAN-2阳性，因此该标记物被认为是监测子宫外范围病例的重要用途之一。

项目成果

Kamoshida S, Yasuda M, et al.: "Immunohistochemical heterogeneity of type 1 blood group antigen expression in testicular germ cell tumors"Oncol Reports. 9. 845-851 (2002)

Kamoshida S、Yasuda M 等人：“睾丸生殖细胞肿瘤中 1 型血型抗原表达的免疫组织化学异质性”Oncol 报告。

Yasuda M, et al.: "Immunohistochemical expression of type-1 carbodydrate antigens : Comuarison of DU-PAN-2 and CA19-9 on pathological and clinical aspects."Acta Histochem Cytochem. 36. 185-192 (2003)

Yasuda M 等人：“1 型碳化物抗原的免疫组织化学表达：DU-PAN-2 和 CA19-9 在病理学和临床方面的比较。”Acta Histochem Cytochem。

Yasuda M, et al.: "Immunohistochemical expression of type-1 carbohydrate antigens : Comparison of DU-PAN-2 and CA19-9 on pathological and clinical aspects."Acta Histochem Cytochem. 36. 185-192 (2003)

Yasuda M 等人：“1 型碳水化合物抗原的免疫组织化学表达：DU-PAN-2 和 CA19-9 在病理学和临床方面的比较。”Acta Histochem Cytochem。

Muramatsu T, Yasuda M, et al.: "Chnicopathological analysis of DU-PAN-2 as a tumor maker for endometrial adenocarcinoma in comparison with CA19-9."Acta Histochem Cytochem. 35. 193-200 (2002)

Muramatsu T、Yasuda M 等人：“与 CA19-9 相比，DU-PAN-2 作为子宫内膜腺癌肿瘤标志物的临床病理学分析。”Acta Histochem Cytochem。

Muramatsu T, Yasuda M, et al.: "Clinicolopathological analysis of DU-PAN-2 as a tumor maker for endometrial adenocarcinoma in comparison with CA19-9."Acta Histochem Cytochem. 35. 193-200 (2002)

Muramatsu T、Yasuda M 等人：“与 CA19-9 相比，DU-PAN-2 作为子宫内膜腺癌肿瘤标志物的临床病理学分析。”Acta Histochem Cytochem。